Introduction {#S1}
============

Obesity is the most important risk factor for insulin resistance and type 2 diabetes ([@B1]), and an increasing threat to both men and women worldwide ([@B2]). It is, however, becoming increasingly evident that handling of nutrients ([@B3], [@B4]), metabolic adaptations to overnutrition ([@B5], [@B6]), and the global prevalence of clinically overt dyslipidemia and diabetes ([@B7], [@B8]) are different for the two sexes. These observations, in addition to concerns about the underrepresentation of women in clinical research ([@B3], [@B9]), have fueled recent interest into sexual dimorphism in metabolism and metabolic disorders.

Insulin resistance is the major contributor to cardiometabolic complications of obesity, including diabetes ([@B10], [@B11]). Several studies have investigated whole-body and/or muscle insulin sensitivity in men and women \[recently reviewed by Lundsgaard and Kiens ([@B12])\]. Most ([@B13]--[@B19]), but not all ([@B20], [@B21]), of the available evidence from euglycemic hyperinsulinemic clamp or arterial--venous balance studies suggests that insulin-stimulated glucose uptake is higher in women than men, indicating that women generally show higher peripheral insulin sensitivity. This may be related to a more favorable adipose tissue distribution in women \[more subcutaneous and less visceral fat compared to men ([@B4])\] as well as to levels of circulating sex hormones, with estrogen having insulin-sensitizing ([@B12]) and anti-inflammatory ([@B22]) properties. This is strengthened by the findings that postmenopausal women rapidly gain visceral fat and become less insulin sensitive ([@B23]), while estrogen administration to postmenopausal women improves insulin action ([@B24]). By contrast, administration of gonadotropin-releasing hormone agonists (to induce short-term hypogonadism) or testosterone does not affect whole-body insulin sensitivity in healthy men ([@B25]).

Few studies have investigated insulin sensitivity in matched severely obese men and women, who are exceptionally prone to develop insulin resistance ([@B26]), or described gender differences in tissue-specific measurements of insulin sensitivity in liver and adipose tissue of men and women. Novel insight into to pathophysiological mechanisms underlying these differences in metabolism may reveal novel targets as well as promote more personalized therapeutic strategies.

In the present study, we aimed to determine the gender differences in glucose metabolism and tissue-specific insulin action using detailed metabolic tracer studies in a cohort of severely obese men and women.

Materials and Methods {#S2}
=====================

Subjects {#S2-1}
--------

To assess the sex-specific differences in glucose metabolism and insulin action, we selected age and body mass index (BMI)-matched men and women (*n* = 46) from a previously described cohort of obese men and women ([@B27]). Subjects were eligible for the present analysis if they were severely obese (BMI \>35 kg/m^2^) and had stable weight (\<5% weight change) for 3 months prior to the study. Subjects were excluded in case of a history of insulin-dependent diabetes, use of alcohol (\>2 U/day) or recreational drugs, use of psychoactive medication, or any somatic disorder except for obesity-related conditions (e.g., dyslipidemia, hypertension, or impaired glucose tolerance).

Subjects completed a medical evaluation including medical history, physical examination, blood tests, and assessment of body composition by bioelectrical impedance analysis (Maltron BF-906, Rayleigh, UK). On a separate visit, subjects underwent a two-step euglycemic hyperinsulinemic clamp for the assessment of glucose metabolism and insulin sensitivity.

All procedures were approved by the Academic Medical Center medical ethics committee and all subjects provided written informed consent in accordance with the Declaration of Helsinki.

Experimental Protocol {#S2-2}
---------------------

Glucose clamp studies were performed according to standard operating procedures, which have been described in detail elsewhere ([@B27]). Briefly, the basal rate of endogenous glucose production (EGP), hepatic insulin sensitivity (expressed as the insulin-mediated suppression of basal EGP), adipose tissue insulin sensitivity \[expressed as the insulin-mediated suppression of circulating free fatty acids (FFA)\], and peripheral insulin sensitivity \[expressed as the insulin-stimulated rate of disappearance (Rd) of glucose\] were assessed after an overnight fast during a two-step euglycemic hyperinsulinemic clamp with infusion of \[6,6-^2^H~2~\]glucose as glucose tracer.

After 2 h of tracer equilibration, insulin infusion was started for 2 h per step at a rate of 20 and 60 mU · m^−2^ · min^−1^ during step 1 and 2, respectively. Plasma glucose was maintained at 5.0 mmol/l by infusion of exogenous glucose enriched with \[6,6-^2^H~2~\]glucose. Three (after tracer equilibration) or five (after each 2-h step of insulin infusion) blood samples with a 5-min interval were drawn to assess tracer enrichment for calculation of EGP and Rd and for measurements of glucoregulatory hormones.

Plasma glucose, glucoregulatory hormones, enrichment of \[6,6^2^H~2~\]glucose (tracer-to-tracee ratio), and lipids were determined, as previously described ([@B27]). EGP and Rd were calculated using modified versions of the Steele equations for the steady state (basal EGP) or non-steady state (during insulin infusion), and expressed as μmol · \[kg fat-free mass (FFM)\]^−1^ · min^−1^ and μmol · (kg body weight)^−1^ · min^−1^, respectively ([@B28], [@B29]).

In a subset of men (*n* = 8) and women (*n* = 19), intrahepatic triglyceride (IHTG) content was assessed by proton magnetic resonance spectroscopy (^1^H-MRS) on the morning of the clamp after an overnight fast. Liver ^1^H-MRS spectra were obtained, as previously described ([@B30]), and IHTG content was defined as the percentage of liver volume comprised of fat.

Statistical Analysis {#S2-3}
--------------------

Data are expressed as mean ± standard error of the mean (SEM), unless stated otherwise. Groups were compared by two-tailed independent samples *t*-test. Correlations were evaluated by Pearson's correlation coefficient. Findings were considered significant if the *p*-value was \<0.05. Analyses were performed using IBM SPSS Statistics 22 (Armonk, NY, USA).

Results {#S3}
=======

We included 46 age and BMI-matched severely obese men and women (Table [1](#T1){ref-type="table"}). Men and women were well-matched in terms of age, BMI, and most other baseline characteristics, but women had higher total body fat content and high-density lipoprotein cholesterol (HDL). Fasting plasma glucose and insulin levels did not differ between men and women. Two obese women were postmenopausal. One woman had (non-insulin-dependent) type 2 diabetes and was treated with oral hypoglycemic agents.

###### 

**Baseline characteristics of included men and women**.

                             Men         Women       *p*
  -------------------------- ----------- ----------- ---------
  *N*                        23          23          --
  Age (years)                48 ± 2      46 ± 2      0.591
  BMI (kg/m^2^)              41 ± 1      41 ± 1      0.832
  Body fat content (%)       43 ± 2      52 ± 1      \<0.001
  Fasting glucose (mmol/l)   5.5 ± 0.1   5.6 ± 0.2   0.728
  Fasting insulin (pmol/l)   105 ± 9     103 ± 9     0.882
  Triglycerides (mmol/l)     1.5 ± 0.2   1.3 ± 0.1   0.228
  Cholesterol (mmol/l)       4.5 ± 0.3   4.9 ± 0.2   0.289
  LDL (mmol/l)               3.1 ± 0.1   3.2 ± 0.2   0.795
  HDL (mmol/l)               1.0 ± 0.1   1.1 ± 0.1   0.039

*Data are mean ± SEM*.

Fasting plasma FFA levels were higher in women (Table [2](#T2){ref-type="table"}). The basal rate of EGP did not differ between men and women (Figure [1](#F1){ref-type="fig"}A), but men had markedly lower insulin-mediated suppression of EGP (Figure [1](#F1){ref-type="fig"}B), indicating that severely obese men are characterized by lower hepatic insulin sensitivity compared to similarly obese women. Plasma glucagon levels during step 1 of the clamp were also higher in men (Table [2](#T2){ref-type="table"}). Insulin-mediated suppression of FFA (Figure [1](#F1){ref-type="fig"}C) and insulin-stimulated Rd of glucose (Figure [1](#F1){ref-type="fig"}D) were not different between both groups, indicating that severely obese men and women are characterized by similar adipose tissue and peripheral tissue insulin sensitivity. We recently defined cutoff values for euglycemic hyperinsulinemic clamp-derived insulin resistance ([@B27]), and 91% of included subjects had Rd \< 37.3 μmol · kg^−1^ · min^−1^, indicative of insulin resistance. Detailed data from the two-step euglycemic hyperinsulinemic clamp studies are presented in Table [2](#T2){ref-type="table"}.

###### 

**Metabolic parameters and fluxes during two-step euglycemic hyperinsulinemic clamp studies (*n* = 46)**.

                                     Men           Women         *p*
  ---------------------------------- ------------- ------------- ---------
  **Basal**                                                      
  Glucose (mmol/l)                   5.5 ± 0.1     5.6 ± 0.2     0.728
  Insulin (pmol/l)                   105 ± 9       103 ± 9       0.882
  Glucagon (ng/l)                    83 ± 5        66 ± 4        0.011
  Cortisol (nmol/l)                  300 ± 36      241 ± 22      0.153
  EGP (μmol · kgFFM^−1^ · min^−1^)   14.4 ± 1.0    15.3 ± 0.5    0.410
  FFA (mmol/l)                       0.57 ± 0.03   0.77 ± 0.03   \<0.001
  **Clamp, step 1**                                              
  Insulin (pmol/l)                   255 ± 18      278 ± 18      0.359
  Glucagon (ng/l)                    76 ± 5        60 ± 4        0.018
  Cortisol (nmol/l)                  235 ± 19      295 ± 25      0.095
  Suppression of EGP (%)             61.7 ± 4.1    72.8 ± 2.5    0.028
  Suppression of FFA (%)             71.6 ± 3.6    76.1 ± 2.6    0.314
  **Clamp, step 2**                                              
  Insulin (pmol/l)                   723 ± 38      740 ± 38      0.749
  Glucagon (ng/l)                    61 ± 4        52 ± 5        0.163
  Cortisol (nmol/l)                  291 ± 34      278 ± 28      0.770
  Rd (μmol · kg^−1^ · min^−1^)       26.2 ± 2.1    22.7 ± 1.7    0.211
  Rd (μmol · kgFFM^−1^ · min^−1^)    48.8 ± 7.3    47.2 ± 3.3    0.846

*Data are mean ± SEM. Basal, after an overnight fast; step 1, after 2 h of low-dose insulin infusion; step 2, after 2 h of high-dose insulin infusion*.

![**Basal glucose metabolism and tissue-specific measurements of insulin action in age and BMI-matched severely obese men and women**. **(A)** Endogenous glucose production (EGP) was assessed in the basal (fasted) state. **(B)** Hepatic insulin sensitivity was defined as the relative suppression of basal EGP by insulin during step 1 of the clamp. **(C)** Adipose tissue insulin sensitivity was defined as the relative suppression of circulating free fatty acids (FFA) by insulin during step 1 of the clamp. **(D)** Peripheral insulin sensitivity was defined as the insulin-stimulated rate of disappearance (Rd) of glucose during step 2 of the clamp. Data are mean ± SEM. \**p* = 0.028.](fendo-06-00182-g001){#F1}

Differences in insulin sensitivity could not be explained by differences in (low-grade) systemic inflammation (C-reactive protein, men vs. women, 7.1 ± 2.6 vs. 11.6 ± 2.6 mg/l, *p* = 0.244) or liver fat content (Figure [2](#F2){ref-type="fig"}). Plasma glucagon levels were not correlated to EGP or hepatic insulin sensitivity during the basal state or step 1 of the clamp in men, women, or all subjects (not shown).

![**Intrahepatic triglyceride (IHTG) content in a subset of severely obese men and women**. Men (*n* = 8) and women (*n* = 19) did not differ in IHTG content by ^1^H-MRS. Data are mean ± SEM.](fendo-06-00182-g002){#F2}

Discussion {#S4}
==========

We show that sexual dimorphism in metabolism is present in severely obese men and women. The current experimental protocol allowed us to quantitatively determine the degree of insulin resistance in the liver, adipose tissue, and muscle. Our results show that, in an age and BMI-matched cohort of severely obese men and women, men have comparable peripheral insulin sensitivity, but lower hepatic insulin sensitivity compared to women. In addition, women have higher fasting plasma levels of FFA, whereas insulin-mediated suppression of FFA levels is similar to men.

Although several previous studies suggest that women may physiologically be inclined to have better muscle insulin sensitivity ([@B13]--[@B17]), both men and women in the present study were severely obese and characterized by moderate-to-severe peripheral insulin resistance compared to a non-obese reference population ([@B27]). Our data, in line with one previous study of obese individuals ([@B21]), suggest that the insulin-sensitizing effects of female sex may be blunted in the context of severe obesity, or that insulin-desensitizing mechanisms in severe obesity may overwhelm the protective mechanisms that exist in lean women.

In the basal state and during prolonged fasting, women rely on lipid oxidation for energy more than men ([@B31]). Women generally have higher basal rates of lipolysis, resulting in higher circulating levels of FFA ([@B20]). In accordance, we also show that severely obese women have higher fasting plasma FFA levels. Notably, infusion of insulin, the major inhibitory regulator of lipolysis, and circulating FFA levels ([@B31]), resulted in similar suppression of FFA in men and women, suggesting that insulin-mediated inhibition of adipose tissue lipolysis does not exhibit sexual dimorphism in obese subjects.

Several mechanisms may explain the difference in hepatic insulin sensitivity between obese men and women. Although the present study did not address the molecular pathophysiology, we did not observe any gender differences in circulating levels of C-reactive protein or IHTG content. These findings may suggest that differences in systemic inflammation or hepatic steatosis, both often implicated in the development of hepatic insulin resistance ([@B32]), did not contribute to the observed sexual dimorphism. Nevertheless, we did not measure local inflammatory signals in the liver nor individual hepatic lipid species, such as diacylglycerol ([@B33]), which may have contributed to hepatic insulin resistance in obese men. In fact, estrogen reduces hepatic diacylglycerol accumulation and improves hepatic insulin resistance in mice ([@B34], [@B35]). Estrogen and estrogen receptor β agonists might thus be considered novel therapeutic targets for hepatic insulin resistance and/or steatosis ([@B36], [@B37]).

Since glucagon stimulates EGP ([@B38]), higher levels of glucagon during the first step of the clamp may have contributed to the lower insulin-mediated suppression of EGP in obese men. However, since the absolute gender difference in glucagon was small and glucagon levels were not directly correlated to EGP or insulin-mediated suppression of EGP in the present study, further research is required to fully elucidate the role of glucagon in explaining sexual dimorphism in metabolism. Other mechanisms, such as sex-specific differences in visceral adipose tissue-derived lipolysis and fatty acid flux ([@B39], [@B40]) or differences in unmeasured glucoregulatory hormones such as growth hormone ([@B41]), may also have contributed to the observed difference in hepatic insulin resistance. Lastly, we did not measure specific adipokines, but it has been shown that circulating adiponectin is lower in men ([@B42]). Since adiponectin reduces EGP in mice ([@B43]), lower levels may be implicated in elevated EGP and/or hepatic insulin resistance.

The observation that severely obese men are prone to develop hepatic insulin resistance is also of clinical relevance. Failure of insulin to appropriately suppress EGP, i.e., hepatic insulin resistance, is an important contributor to the development of hyperglycemia and (pre)diabetes ([@B44]--[@B46]). A male predisposition to develop obesity-related hepatic insulin resistance may thus contribute to the higher global prevalence of diabetes in men ([@B7]). In accordance, prevention of type 2 diabetes by metformin, an oral hypoglycemic agent that primarily targets hepatic insulin resistance ([@B47]), appeared to be most effective in obese and male prediabetes patients ([@B48]). Further understanding of the precise metabolic defects in (obese) men and women will help to personalize treatment strategies.

We acknowledge that the contribution of adipose tissue glucose uptake to whole-body insulin-stimulated glucose uptake has not been clearly established, and estimates range from \~4 to 33% of total glucose flux ([@B49], [@B50]). Differences in body composition \[i.e., women typically have twice the adipose tissue mass compared to men with the same BMI ([@B4], [@B12])\] may thus influence study results when metabolic fluxes, such as the Rd of glucose, are expressed per kilogram of body weight or kilogram of fat-free mass. In the present study, however, Rd was comparable for severely obese men and women when expressed per kilogram of body weight (Figure [1](#F1){ref-type="fig"}D) or fat-free body mass (Table [2](#T2){ref-type="table"}), suggesting that differences in body fat content between men and women did not influence the main findings.

Unfortunately, we did not have data on the menstrual status of included women and, therefore, could not take this into account. Women generally do not undergo major changes in peripheral insulin sensitivity throughout the menstrual cycle ([@B12]), but plasma sex hormones may vary considerably, and we cannot rule out an effect of menstrual status on measurements of hepatic and/or adipose tissue insulin resistance. We also acknowledge that glucose tolerance and HbA~1c~ tests were not performed in the present study. We thus cannot rule out that some individuals with normal fasting glucose would otherwise be diagnosed with impaired glucose tolerance or type 2 diabetes on the basis of those tests. Finally, sensitivity analysis did not reveal any differences in our results when all analyses were repeated excluding two postmenopausal women and/or one woman with pre-existing type 2 diabetes.

In conclusion, we show that insulin sensitivity of adipose tissue and peripheral tissues is similarly impaired in severely obese men and women, but these men are characterized by lower hepatic insulin sensitivity. A predisposition to develop obesity-related hepatic insulin resistance may contribute to the higher prevalence of diabetes in obese men. Further studies are required to elucidate the molecular mechanisms underlying the observed sexual dimorphism in obesity-related insulin resistance.
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